Enter inventor name

Hans-Willi Jansen

USPTO Granted Patents = 19 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 4.9

ph-index = 6

Forward Citations = 104(Granted Patents)

Location History:

Niedemhausen, DE (2003)
Neidernhausen, DE (2008)
Niedernhausen, DE (1999 - 2009)

Company Filing History:

13 out of 330

Aventis Pharma Deutschland, Gmbh

patents

3 out of 6,662

Hoechst Aktiengesellschaft

patents

2 out of 1,829

Sanofi-a Ventis Deutschland Gmbh

patents

4. 1 out of 18

Hoechst Marion Roussel Deutschland Gmbh

patents

Years Active: 1999-2009

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7550257 - Process for identifying substances which modulate the activity of hyperpolarization-activated cation channels (2009-06-23),

2. 7442717 - Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid (2008-10-28),

3. 6979532 - Process for identifying substances which modulate the activity of hyperpolarization-activated cation channels (2005-12-27),

4. 6825231 - Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them (2004-11-30),

5. 6737423 - Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them (2004-05-18),

6. 6703411 - Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them (2004-03-09),

7. 6617344 - Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them (2003-09-09),

8. 6593352 - Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker (2003-07-15),

9. 6573288 - Substituted sulphonyl cyanamides, method for producing same and their use as medicament (2003-06-03),

10. 6486189 - Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them (2002-11-26),

11. 6451781 - Substituted acylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them (2002-09-17),

12. 6369069 - Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament (2002-04-09),

13. 6339077 - Substituted 4-benzylaminoquinolines and their hetero analogs, process for their preparation, pharmaceuticals containing these compounds and use thereof (2002-01-15),

14. 6335451 - Five-membered heterocycles having biphenylsulfonyl substitution, with sulfonylcyanamide side chain, compositions containing them, and methods of using them (2002-01-01),

15. 6331546 - Use of 2-amino-3,4-dihydroquinazolines for the production of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions (2001-12-18),

Title: Innovations and Contributions of Hans-Willi Jansen

Introduction: Hans-Willi Jansen is a prolific inventor based in Niedernhausen, Germany. With an impressive portfolio of 19 patents, his work significantly contributes to the fields of pharmacology and biotechnology. His innovative approaches are aimed at addressing various health-related challenges, underlining his importance in today's medical landscape.

Latest Patents: Among his notable inventions is a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels. This invention enhances the understanding and manipulation of these crucial cellular components. Another recent patent involves substituted 2-aminoimidazoles, outlining a process for their preparation and their application as medicaments or diagnostic aids. These compounds hold promise for treating a range of disorders, including renal issues, respiratory problems like snoring and sleep apnea, as well as complications arising from strokes.

Career Highlights: Hans-Willi Jansen has made significant strides in his career by working with reputable companies such as Aventis Pharma Deutschland GmbH and Hoechst Aktiengesellschaft. His experience in these firms has provided him with a strong foundation in pharmaceutical research and development, allowing him to translate scientific hypotheses into tangible medical solutions.

Collaborations: Throughout his career, Jansen has collaborated with esteemed colleagues, including Andreas Gerhard Weichert and Heinz-Werner Kleemann. These partnerships have not only facilitated the exchange of innovative ideas but have also amplified the impact of their collective research contributions.

Conclusion: Hans-Willi Jansen exemplifies the spirit of innovation in the realm of medical science. His 19 patents reflect a commitment to improving patient outcomes through inventive solutions. As he continues to explore new avenues for research and development, the medical community eagerly anticipates the potential benefits of his ongoing work.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com